Provenge (sipuleucel-T), by Dendreon Pharmaceuticals, is superior to Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at prolonging the lives of men with metastatic castration-resistant prostate cancer (mCRPC) when added at any point in a treatment regimen, according to a real-life study in the U.S. The study, “A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer,” was published in the journal Advances in Therapy. “Men with mCRPC who received…
You must be logged in to read/download the full post.
The post Provenge Improves Survival in mCRPC Patients Over Xtandi, Zytiga, Real-world Study Finds appeared first on BioNewsFeeds.